6-day-old C57BL/J6 mice (Jackson Laboratory, Bar Harbor, ME) were used in the experiments as described before.8 (link),32 (link) In the interaction studies, CsA (10mg/kg) was administered to mice via intraperitoneal injection 30 minutes before treatment with isoflurane or desflurane. Whole brain tissues or hippocampus tissues of mice were harvested at the end of isoflurane or desflurane anesthesia (see Supplementary Methods ).
>
Chemicals & Drugs
>
Organic Chemical
>
Desflurane
Desflurane
Desflurane is a volatile anesthetic agent used for the induction and maintenance of general anesthesia.
It is a halogenated ether that is less soluble in blood than other volatile anesthetics, allowing for rapid changes in anesthetic depth.
Desflurane has a low potency and pungent odor, which can make it less tolerable for induction of anesthesia in some patients.
Its low blood/gas partition coefficient enables fast induction and emergence from anesthesia.
Desflurane is commonly used in ambulatory and short-duration surgical procedures due to its favorable pharmacokinetic profile.
Reserchers can use PubCompare.ai's AI-driven protocol comparions to optimize Desflurane research, easily locating and comparing protocols from literatur, pre-prints, and patents to identify the best protocols and products for their needs.
Leveraging the power of AI can take Desflurane research to the next level.
It is a halogenated ether that is less soluble in blood than other volatile anesthetics, allowing for rapid changes in anesthetic depth.
Desflurane has a low potency and pungent odor, which can make it less tolerable for induction of anesthesia in some patients.
Its low blood/gas partition coefficient enables fast induction and emergence from anesthesia.
Desflurane is commonly used in ambulatory and short-duration surgical procedures due to its favorable pharmacokinetic profile.
Reserchers can use PubCompare.ai's AI-driven protocol comparions to optimize Desflurane research, easily locating and comparing protocols from literatur, pre-prints, and patents to identify the best protocols and products for their needs.
Leveraging the power of AI can take Desflurane research to the next level.
Most cited protocols related to «Desflurane»
Anesthesia
Brain
Desflurane
Injections, Intraperitoneal
Isoflurane
Mice, House
Mice, Inbred C57BL
Seahorses
Tissues
Anesthesia
Anesthetics
Animals
Arteries
Bupivacaine
Carotid Arteries
Cell Respiration
Common Carotid Artery
Desflurane
Isoflurane
Mice, House
Murine Plus
Neck
Operative Surgical Procedures
Oxygen Saturation
Pneumogastric Nerve
Pulse Rate
Rate, Heart
Rectum
Sevoflurane
Sterility, Reproductive
Subcutaneous Injections
Sutures
Tissues
Trachea
Vaporizers
Wounds
Using this hemodynamic model for nociceptive responses, we prospectively evaluated the differences in nociceptive responses just after skin incision between laparoscopic surgery (n=10) and open abdominal surgery (n=10). All eligible patients underwent laparoscopic or open gastrectomy (n=5 or 4), otherwise, laparoscopic or open hysterectomy (n=5 or 6) in 2017. General anesthesia was induced with propofol (1.5 mg/kg), fentanyl (2 μg/kg), and 1 MACage of desflurane. Rocuronium (0.9 mg/kg) was injected intravenously to facilitate endotracheal intubation. Mechanical ventilation was performed using an oxygen concentration of 40% to obtain normocapnia (end-tidal carbon dioxide range 35–40 mmHg). After induction, anesthesia was maintained with 0.7 MACage of desflurane. Intravenous remifentanil (0.04–0.05 μg/kg/min) was continuously infused to keep the effect site concentration at 1.0 ng/mL before and after the start of skin incision. Peripheral nerve blocks were not performed. Three variables of HR, SBP, and PI were recorded before, 0.5 min, and 1 min after the skin incision. Nociceptive responses were then calculated from the developed hemodynamic model using computer software (Microsoft Excel, Microsoft, Redmond, WA) to determine whether this model discerns between nociceptive levels during small skin incision for laparoscopic surgery vs. large skin incision for open abdominal surgery. Vasoactive agents were not administered until 1 min after the skin incision. At 1 min after the skin incision, the continuous dose of remifentanil was increased to 0.1–0.5 μg/kg/min with additional intravenous fentanyl to suppress any further increase in nociceptive responses.
To calculate MACage, which is the MAC for a given age normalized to MAC40 [14 (link)], we used MAC40 as 2.0 for sevoflurane and 6.0 for desflurane [15 ] to calculate MACage.
To calculate MACage, which is the MAC for a given age normalized to MAC40 [14 (link)], we used MAC40 as 2.0 for sevoflurane and 6.0 for desflurane [15 ] to calculate MACage.
Abdomen
Anesthesia
Carbon dioxide
Desflurane
Fentanyl
Gastrectomy
General Anesthesia
Hemodynamics
Hysterectomy
Intubation, Intratracheal
Laparoscopy
Mechanical Ventilation
Nerve Block
Operative Surgical Procedures
Oxygen
Patients
Propofol
Remifentanil
Rocuronium
Sevoflurane
Skin
Surgical Wound
The primary end point was overall survival, which was compared between the propofol and desflurane groups. The survival time was defined as the interval between the date of surgery and the date of death or February 11, 2019, for those who were censored. All data are presented as mean ± standard deviation (SD) or number (percentage).
Mortality rates and patient characteristics were compared between the groups treated with the different anesthetics using Student’s t test or the chi-square test. The survival according to the anesthetic technique was depicted visually in a Kaplan–Meier survival curve. The association between the anesthetic techniques (propofol or desflurane) and survival was analyzed by the Cox proportional-hazards model with and without adjustment for the abovementioned variables. Because significant interactions with the two anesthetic techniques (propofol or desflurane) were found, we also performed subgroup analyses for TNM stage, postoperative recurrence, and postoperative metastases formation.
Propensity score (PS) matching with IBM SPSS Statistics 22.0 was used to select for the most similar PSs for preoperative variables (with calipers set at 0.2 SD of the logit of the PS) across each anesthesia: propofol or desflurane in a 1:1 ratio, to make sure the comparability between propofol and desflurane anesthesia before the surgery. Two-tailed P-values less than 0.05 were considered statistically significant.
Mortality rates and patient characteristics were compared between the groups treated with the different anesthetics using Student’s t test or the chi-square test. The survival according to the anesthetic technique was depicted visually in a Kaplan–Meier survival curve. The association between the anesthetic techniques (propofol or desflurane) and survival was analyzed by the Cox proportional-hazards model with and without adjustment for the abovementioned variables. Because significant interactions with the two anesthetic techniques (propofol or desflurane) were found, we also performed subgroup analyses for TNM stage, postoperative recurrence, and postoperative metastases formation.
Propensity score (PS) matching with IBM SPSS Statistics 22.0 was used to select for the most similar PSs for preoperative variables (with calipers set at 0.2 SD of the logit of the PS) across each anesthesia: propofol or desflurane in a 1:1 ratio, to make sure the comparability between propofol and desflurane anesthesia before the surgery. Two-tailed P-values less than 0.05 were considered statistically significant.
Full text: Click here
Anesthesia
Anesthetics
Desflurane
Neoplasm Metastasis
Operative Surgical Procedures
Patients
Propofol
Recurrence
Student
All animal experiments were carried out at the Helmholtz Zentrum Dresden Rossendorf (HZDR) according to the guidelines of German Regulations for Animal Welfare and have been approved by the Landesdirektion Dresden (24-9165.40-4, 24.9168.21-4/2004-1). Four weeks old female NMRI-Foxn1nu/Foxn1nu mice were purchased from JANVIER LABS (St. Berthevin, France). General anesthesia was induced with 10% (v/v) and maintained with inhalation of 8% (v/v) desflurane (Suprane, Baxter, Germany) in 30/10% (v/v) oxygen/air. Luminescence imaging (exposure times 1 s, 10 s, and 60 s) was performed using a dedicated small animal multimodal imaging system (Xtreme, Bruker, Germany) 10 min after i.p. injection of 200 μl of luciferin (15 mg/ml) (Thermofisher, Dreieich, Germany). In parallel an X-RAY photograph was taken from the same animals at the same position.
Full text: Click here
Animals
Desflurane
Females
General Anesthesia
Inhalation
Luciferins
Luminescence
Magnetic Resonance Imaging
Mice, House
Oxygen
Radiography
Suprane
Most recents protocols related to «Desflurane»
This retrospective cohort study included patients aged ≥ 18 years who underwent noncardiac surgery, including general, gynecological, otolaryngological, plastic, and urological surgery, under general anesthesia using inhalation anesthetics (desflurane or sevoflurane) and PI monitoring from February to August 2021 in a university hospital. Patients were excluded if clinical or vital data were missing, their vital records had interruptions, or if information was lacking regarding the inhalation agent, PI, or blood pressure (noninvasive or invasive arterial pressure). To account for the differences in their clinical characteristics, patients administered desflurane and sevoflurane were matched 1:1 by propensity score. This manuscript adheres to the applicable STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines10 (link).
Full text: Click here
Anesthetics, Inhalation
Blood Pressure
Desflurane
General Anesthesia
Inhalation
Operative Surgical Procedures
Patients
Sevoflurane
Urologic Surgical Procedures
After entry to the operating room, HR, BP, and peripheral oxygen saturation were recorded for all patients; subsequently, dexamethasone 0.1 mg/kg and glycopyrrolate 0.005 mg/kg were administered. After pre-oxygenation, propofol 2 mg/kg and rocuronium 0.8 mg/kg were administered. The anesthesia was maintained with desflurane and was adjusted according to the bispectral index (BIS) level goal, which is from 30 to 60.
In the case of the T group, the Ce of remifentanil before intubation was set to 5.0–7.0 ng/mL using the syringe pump with a Minto model (Orchestra® Base Primea, Fresenius Kabi, VL, France) [17 (link)]. During surgery, the patients’ BP and HR were monitored, and the Ce of remifentanil was adjusted within the range of 1.0–3.0 ng/mL. In the M group, 0.7–1 µg/kg of remifentanil was administered before intubation using an infusion pump (Terufusion® Infusion Pump, Terumo, Tokyo, Japan). During surgery, remifentanil was titrated within the range of 0.05–0.2 µg/min/kg against HR and BP within a 20% range of baseline measurements. In both groups, if vital signs could not be controlled by remifentanil alone, a vasoconstrictor (phenylephrine, 50 µg) or vasodilator (nicardipine, 500 µg) was administered.
Remifentanil was discontinued during skin closure, and desflurane was discontinued when the position was changed from lithotomy to supine after surgery, and glycopyrrolate 0.005 mg/kg and pyridostigmine 0.25 mg/kg were administered as reversal agents of neuromuscular blockers. At the end of surgery, fentanyl-based (17.5 µg/kg) intravenous patient-controlled analgesia was administered to all of the participants until POD2. Additional opioids or analgesics were administered when patients complained of pain with an NRS pain score of ≥3 or if the patient required analgesics. In the PACU, fentanyl was administered as a bolus dose of 1 µg/kg. On POD1, intravenous acetaminophen 750 mg and per os ibuprofen 200 mg were used, and on POD2, ibuprofen was administered alone.
In the case of the T group, the Ce of remifentanil before intubation was set to 5.0–7.0 ng/mL using the syringe pump with a Minto model (Orchestra® Base Primea, Fresenius Kabi, VL, France) [17 (link)]. During surgery, the patients’ BP and HR were monitored, and the Ce of remifentanil was adjusted within the range of 1.0–3.0 ng/mL. In the M group, 0.7–1 µg/kg of remifentanil was administered before intubation using an infusion pump (Terufusion® Infusion Pump, Terumo, Tokyo, Japan). During surgery, remifentanil was titrated within the range of 0.05–0.2 µg/min/kg against HR and BP within a 20% range of baseline measurements. In both groups, if vital signs could not be controlled by remifentanil alone, a vasoconstrictor (phenylephrine, 50 µg) or vasodilator (nicardipine, 500 µg) was administered.
Remifentanil was discontinued during skin closure, and desflurane was discontinued when the position was changed from lithotomy to supine after surgery, and glycopyrrolate 0.005 mg/kg and pyridostigmine 0.25 mg/kg were administered as reversal agents of neuromuscular blockers. At the end of surgery, fentanyl-based (17.5 µg/kg) intravenous patient-controlled analgesia was administered to all of the participants until POD2. Additional opioids or analgesics were administered when patients complained of pain with an NRS pain score of ≥3 or if the patient required analgesics. In the PACU, fentanyl was administered as a bolus dose of 1 µg/kg. On POD1, intravenous acetaminophen 750 mg and per os ibuprofen 200 mg were used, and on POD2, ibuprofen was administered alone.
Full text: Click here
Acetaminophen
Analgesics
Analgesics, Opioid
Anesthesia
Cell Respiration
Desflurane
Dexamethasone
Fentanyl
Glycopyrrolate
Ibuprofen
Infusion Pump
Intubation
Neuromuscular Blocking Agents
Nicardipine
Operative Surgical Procedures
Pain
Patient-Controlled Analgesia
Patients
Phenylephrine
Propofol
Pyridostigmine
Remifentanil
Rocuronium
Saturation of Peripheral Oxygen
Signs, Vital
Skin
Syringes
Vasoconstrictor Agents
Vasodilator Agents
The primary outcome was the incidence of PONV within 48 h after surgery. PONV was evaluated through patient interviews and medical record reviews at the PACU, postoperative days (POD) 1, and POD2. It was defined as the time at which the patient complained of nausea or vomiting, or when antiemetic drugs were administered.
The secondary outcomes included numerical rating scale (NRS) pain scores in the PACU, POD1, and POD2. Perioperative blood pressure (BP), heart rate (HR), emergence time to eye opening, tracheal extubation, and exit from the operating room after desflurane cessation were evaluated. The number of patients who were administered opioids or analgesics in the PACU, POD1, and POD2 were recorded. Additionally, the PACU LOS and postoperative hospital LOS were recorded.
The secondary outcomes included numerical rating scale (NRS) pain scores in the PACU, POD1, and POD2. Perioperative blood pressure (BP), heart rate (HR), emergence time to eye opening, tracheal extubation, and exit from the operating room after desflurane cessation were evaluated. The number of patients who were administered opioids or analgesics in the PACU, POD1, and POD2 were recorded. Additionally, the PACU LOS and postoperative hospital LOS were recorded.
Full text: Click here
Analgesics
Antiemetics
Blood Pressure
Desflurane
Nausea
Operative Surgical Procedures
Opioids
Pain
Patients
Postoperative Nausea and Vomiting
Rate, Heart
Tracheal Extubation
Based on the medical records, the overall incidence of PONV was evaluated from PACU to POD2.
The participants’ HR and BP were recorded at the initial visit and before and after tracheal intubation, skin incision, carbon dioxide insufflation, specimen removal, and skin closure stage. The total amount of remifentanil and other drugs administered during the surgery was recorded. The duration of emergence from desflurane cessation to eye opening, tracheal extubation, and exit from the operating room was recorded.
After leaving the operating room, the participants’ HR and BP were measured in the PACU. The incidence of PONV was recorded in the PACU, POD1, and POD2. Additionally, the opioid and analgesic requirements in the PACU, POD1 and POD2, PACU LOS, and postoperative hospital LOS were also evaluated.
The participants’ HR and BP were recorded at the initial visit and before and after tracheal intubation, skin incision, carbon dioxide insufflation, specimen removal, and skin closure stage. The total amount of remifentanil and other drugs administered during the surgery was recorded. The duration of emergence from desflurane cessation to eye opening, tracheal extubation, and exit from the operating room was recorded.
After leaving the operating room, the participants’ HR and BP were measured in the PACU. The incidence of PONV was recorded in the PACU, POD1, and POD2. Additionally, the opioid and analgesic requirements in the PACU, POD1 and POD2, PACU LOS, and postoperative hospital LOS were also evaluated.
Full text: Click here
Analgesics
Carbon dioxide
Desflurane
Insufflation
Intubation, Intratracheal
Operative Surgical Procedures
Opioids
Pharmaceutical Preparations
Postoperative Nausea and Vomiting
Remifentanil
Skin
Tracheal Extubation
All patients were given propofol, fentanyl with rocuronium during induction of anesthesia. For patients with total intravenous anesthesia, propofol, remifentanil, and rocuronium were used for general anesthesia maintenance. For patients undergoing volatile anesthesia, desflurane or sevoflurane, remifentanil and rocuronium are used for general anesthesia maintenance. The combined use of epidural anesthesia depended on the clinician’s judgment.
Full text: Click here
Anesthesia
Anesthesia, Intravenous
Desflurane
Epidural Anesthesia
Fentanyl
General Anesthesia
Patients
Propofol
Remifentanil
Rocuronium
Sevoflurane
Top products related to «Desflurane»
Sourced in United States, Germany
Desflurane is a halogenated anesthetic agent used for the induction and maintenance of general anesthesia. It is a colorless, non-flammable, and volatile liquid.
Sourced in Germany
Suprane is a general anesthetic medication used in surgical procedures. It is a volatile liquid that is vaporized and administered through inhalation. Suprane provides anesthesia and pain relief during medical operations.
Sourced in United States
The Galaxy R CO2 chamber is a laboratory equipment designed to maintain a controlled carbon dioxide (CO2) environment for cell culture applications. It provides a reliable and consistent CO2 concentration to support the growth and development of cells in vitro.
Sourced in United States
The Gemstar Yellow is a laboratory equipment product designed for various applications in scientific research and analysis. It serves as a versatile tool with a core function of providing consistent and reliable light output for various experimental setups. The product specifications and technical details are available upon request.
Sourced in France
The Rj:NMRI-Foxn1nu/nu is a laboratory equipment designed for specific research applications. It serves as a tool for conducting experiments, but a detailed description of its core function cannot be provided while maintaining an unbiased and factual approach. Further information may be available from the manufacturer or subject matter experts.
Sourced in United States, Germany, United Kingdom
Sevoflurane is a volatile anesthetic agent used in laboratory settings. It is a colorless, sweet-smelling liquid that is commonly used for the induction and maintenance of general anesthesia. Sevoflurane is known for its rapid onset and recovery times, making it a widely-used choice in various laboratory procedures and experiments.
Sourced in United States, Germany, Morocco
The In-Vivo Xtreme imaging system is a multi-modal imaging platform designed for small animal research. It provides high-resolution, quantitative imaging capabilities for a variety of preclinical applications.
The Fiber Optic System is a laboratory equipment designed to work with fiber optic cables. It provides a platform for transmitting and receiving optical signals through fiber optic technology.
Sourced in United States, United Kingdom, Germany, China, Canada, Italy, Japan, Morocco, Israel, Australia, France, Sao Tome and Principe, Denmark
GAPDH is an enzyme that catalyzes the sixth step of glycolysis, the metabolic pathway that converts glucose into energy. It is responsible for the conversion of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate. GAPDH is commonly used as a control or reference gene in molecular biology experiments.
Sourced in Germany, United States
The Ultraviolet imaging system is a specialized lab equipment designed for the detection and analysis of samples under ultraviolet light. It provides a precise and controlled environment for capturing images and data from materials that exhibit fluorescence or other UV-reactive properties.
More about "Desflurane"
Desflurane is a potent volatile anesthetic agent commonly used for the induction and maintenance of general anesthesia.
It is a halogenated ether that is less soluble in blood compared to other volatile anesthetics, allowing for rapid changes in anesthetic depth.
Desflurane has a low potency and a pungent odor, which can make it less tolerable for some patients during induction.
However, its low blood/gas partition coefficient enables fast induction and emergence from anesthesia, making it well-suited for ambulatory and short-duration surgical procedures.
Researchers can leverage PubCompare.ai's AI-driven protocol comparisons to optimize Desflurane research.
This powerful tool allows them to easily locate and compare protocols from literature, pre-prints, and patents, helping them identify the best protocols and products for their needs.
By harnessing the power of AI, researchers can take their Desflurane research to new heights, exploring synergies with related agents like Suprane, Sevoflurane, and Fiber optic systems, and utilizing advanced imaging technologies like the Galaxy R CO2 chamber, In-Vivo Xtreme, and Ultraviolet imaging system.
With the ability to quickly identify and compare relevant protocols, researchers can streamline their workflow, save time, and focus on driving innovative discoveries in the field of anesthesiology.
Leveraging the insights gained from MeSH term descriptions and AI-powered protocol comparisons can help unlock the full potential of Desflurane research and unlock new avenues for exploration.
It is a halogenated ether that is less soluble in blood compared to other volatile anesthetics, allowing for rapid changes in anesthetic depth.
Desflurane has a low potency and a pungent odor, which can make it less tolerable for some patients during induction.
However, its low blood/gas partition coefficient enables fast induction and emergence from anesthesia, making it well-suited for ambulatory and short-duration surgical procedures.
Researchers can leverage PubCompare.ai's AI-driven protocol comparisons to optimize Desflurane research.
This powerful tool allows them to easily locate and compare protocols from literature, pre-prints, and patents, helping them identify the best protocols and products for their needs.
By harnessing the power of AI, researchers can take their Desflurane research to new heights, exploring synergies with related agents like Suprane, Sevoflurane, and Fiber optic systems, and utilizing advanced imaging technologies like the Galaxy R CO2 chamber, In-Vivo Xtreme, and Ultraviolet imaging system.
With the ability to quickly identify and compare relevant protocols, researchers can streamline their workflow, save time, and focus on driving innovative discoveries in the field of anesthesiology.
Leveraging the insights gained from MeSH term descriptions and AI-powered protocol comparisons can help unlock the full potential of Desflurane research and unlock new avenues for exploration.